Skip to content

Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed Cognitive Fusion TRUS Guided Prostate Biopsy (PROBIOP)

Comparison of Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed TRUS Guided (Cognitive Fusion) Prostate Biopsy in PIRADS 4 and 5 Lesions: A Pilot Study to Assess Diagnostic Performance and Patient Safety

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05137561
Acronym
PROBIOP
Enrollment
217
Registered
2021-11-30
Start date
2021-10-25
Completion date
2024-06-30
Last updated
2025-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer, Prostate Neoplasm

Brief summary

The present study aimed to compare the diagnostic accuracy, radiation exposure, complication rates between 68Ga-PSMA PET/CT guided robotic arm assisted prostate biopsy and MRI directed TRUS guided prostate biopsy in PIRADS 4/5 lesions.

Detailed description

To compare the diagnostic yield of Robotic-arm assisted 68Ga PSMA PET/CT guided prostate biopsy and MRI directed TRUS guided prostate biopsy in patients with PIRADS grading 4/5. To compare the visual pain index of the patients between two arms during the procedure. To compare the complication rates between the two arms during and after the procedure for a period of 2 weeks

Interventions

PROCEDUREPSMA PET guided prostate biopsy

PSMA PET-guided prostate biopsy from PSMA avid prostatic lesion will be done.

PROCEDUREMRI directed TRUS guided prostate biopsy

TRUS guided MR directed Cognitive fusion prostate biopsy based on the PIRADS scoring

Sponsors

Post Graduate Institute of Medical Education and Research, Chandigarh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Simple randomization using RRApp

Eligibility

Sex/Gender
MALE
Age
45 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

1. PIRADS 4 and 5 prostate lesions and PIRADS \</= 3 prostate lesions with high clinical suspicion. 2. Patients who are included in the study will be randomly allocated into either PSMA PET/CT guided biopsy or TRUS guided biopsy using simple randomization in RRApp

Exclusion criteria

1. Patients with acute prostatitis/ urine culture positive. 2. Patients with pre-existing bleeding diathesis like hemophilia, coagulopathy defined by INR ≥ 1.2, and Platelet counts ≤ 80,000/mm3 3. Patients who refuse to provide the written informed consent 4. Non-cooperative patients

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic yield of mpMRI directed vs PET/CT directed prostate biopsy12 monthsThe number of participants (with percentages) in whom the biopsy procedure yielded a tissue specimen adequate for a definite pathological diagnosis and detection of PCa in both arms
Diagnostic performance of mpMRI directed vs PET/CT directed prostate biopsy12 monthsThe sensitivity, specificity and accuracy of mpMR directed TRUS guided (cognitive fusion) and PSMA PET/CT directed biopsy will be compared.

Secondary

MeasureTime frameDescription
Incidence of procedure related complicationsthree monthsThe procedure-related complications in the number and percentage of recruiting participants will be tabulated.

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 20, 2026